Thursday, December 11, 2025

We Humbly Thank You, Ranier

›
By:  Brandon M. Macsata , ADAP CEO Since January 2022, Ranier Simons has delivered the weekly ADAP Blog to thousands of stakeholders across ...
Thursday, December 4, 2025

Alternative Funding Programs for Prescription Drugs Are Putting Patient Lives at Risk

›
By:  Ranier Simons , ADAP Blog Guest Contributor As part of ADAP Advocacy’s continued spotlight on the dangers of counterfeit prescription d...
Wednesday, November 26, 2025

Counterfeit Drug Rings Increasingly Peddling Fraudulent HIV, Cancer, and GLP-1 Medications

›
By:  Ranier Simons , ADAP Blog Guest Contributor Healthcare expenditures remain a significant source of contention for many Americans. A rec...
Thursday, November 20, 2025

Why the 340B ACCESS Act Prioritizes Patients

›
By: Marucs J. Hopkins , ADAP 340B Consultant In September 2025, Representatives Earl L. “Buddy” Carter (R-GA) and Diana Harshberger (R-TN) i...
Thursday, November 13, 2025

Trump's Memorandum on Pharma DTC Advertising is a Solution in Search of a Problem

›
By:  Ranier Simons , ADAP Blog Guest Contributor Adding to the growing list of edicts issued by the Trump Administration is a presidential m...
Thursday, November 6, 2025

Opioid Use Disorder Among Medicare Beneficiaries

›
By:  Ranier Simons , ADAP Blog Guest Contributor The United States has the highest levels of opioid consumption worldwide (Cornell et al., 2...
Thursday, October 30, 2025

Why are Price Cap Proposals on Medicines Dangerous to Pharmacies and Patients?

›
By: Shabbir Imber Safdar , ADAP Advocacy Board Member and Executive Director, Partnership for Safe Medicines ** Reposted with Permission fro...